A small New York-based investment bank with less than 50 employees has picked up its latest multibillion-dollar mandate advising on the second-largest pharmaceuticals deal on record.

Dyal Co, set up by former Goldman Sachs dealmaker Gordon Dyal less than three years ago, has been named as one of the advisers to Bristol-Myers Squibb on its $74bn takeover of US rival Celgene.